Secretion imbalance between tumour necrosis factor and its inhibitor in inflammatory bowel disease

Noguchi, Mitsunori; Hiwatashi, Nobuo; Liu, Z; Toyota, Takayoshi

doi:10.1136/gut.43.2.203

Cited by 106 publications

(67 citation statements)

References 49 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, in patients in remission, sTNFR1 and sTNFR2 levels were comparable to those in controls. Similar results were reported by Spoettl et al 9 and Hudson et al 10 In contrast, Noguchi et al 27 performed ±319.35 pg/ml, respectively, P <0.001) compared with the subgroups in remission. There were no differences in TNF-α, sTNFR1, and sTNFR2 levels depending on disease location and duration¸ smoking status, development of exacerbated or recurrent disease in the follow-up period, and the type of therapy either in CD or UC.…”

Section: 17supporting

confidence: 87%

See 1 more Smart Citation

TNF‑α and soluble forms of TNF receptors 1 and 2 in the serum of patients with Crohn’s disease and ulcerative colitis

Owczarek¹,

Cibor²,

Głowacki³

et al. 2012

Polish Archives of Internal Medicine

View full text Add to dashboard Cite

IntroductIon Soluble forms of tumor necrosis factor (TNF) membrane receptors 1 and 2 (sTNFR1 and sTNFR2) are present in body fluids. Their higher concentrations are observed in a number of diseases, including inflammatory bowel diseases (IBDs). sTNFR1 and sTNFR2 are capable of binding TNF-α, acting as an inhibitor that competes with a membrane receptor. The results of the available studies on sTNFR1 and sTNFR2 concentrations in IBDs and their association with disease activity are ambiguous.objectIves The aim of the study was to assess sTNFR1 and sTNFR2 concentrations and their correlation with disease activity in patients with IBD.PAtIents And methods Plasma levels of TNF-α, sTNFR1, and sTNFR2 were measured in 55 consecutive patients with ulcerative colitis (UC), 50 subjects with Crohn's disease (CD), and 41 healthy controls. We assessed the associations of those markers with other inflammatory markers, disease activity and location, type of treatment, and complications.results Positive correlations were observed between CD activity and sTNFR1 and sTNFR2 levels (r = 0.42 for both, P <0.01) as well as between UC activity and sTNFR1 and sTNFR2 levels (r = 0.63, P <0.0001; r = 0.47, P <0.001; respectively). TNF-α levels correlated only with CD activity (r = 0.29, P <0.05). In patients with nonactive UC, higher sTNFR2 levels were observed compared with controls. In patients with CD, higher TNF-α and sTNFR2 levels were demonstrated in patients who developed complications.conclusIons sTNFR1 and sTNFR2 are more sensitive inflammatory markers than TNF-α in the assessment of disease activity in patients with CD and UC. Higher sTNFR2 levels are observed in patients with CD and complications.

show abstract

Section: 17supporting

confidence: 87%

“…The investigators failed to demonstrate differences between patients in remission and controls. 27 In our study, we observed that sTNFR1 and sTNFR2 levels in patients with CD were higher not only during exacerbation but also during remission compared with controls.…”

Section: 17supporting

confidence: 45%

TNF‑α and soluble forms of TNF receptors 1 and 2 in the serum of patients with Crohn’s disease and ulcerative colitis

Owczarek¹,

Cibor²,

Głowacki³

et al. 2012

Polish Archives of Internal Medicine

View full text Add to dashboard Cite

show abstract

“…Expression of TNFa was also increased in gastric lesions and inflamed colonic mucosa of patients with IBD (Noach et al, 1994;Noguchi et al, 1998). However, reports on the role of TNFa have been conflicting, potentially acting as A paradigm of the Yin-Yang interplay between inflammation and cancer S Danese and A Mantovani either a tumor-promoting or tumor-destructive factor (Szlosarek et al, 2006).…”

Section: Cytokinesmentioning

confidence: 99%

“…Indeed, several clinical studies provide evidence that TNFa contributes to the development of human cancers, including CRC. TNFa is found in the microenvironment of many types of tumor, including breast, ovarian, colorectal, prostate, melanoma, lymphomas and leukemia (Szlosarek and Balkwill, 2003;Balkwill, 2009) Specifically, in CRC, the mRNA and protein levels of TNFa are increased to abnormal levels in the preneoplastic inflamed colonic mucosa (Noguchi et al, 1998).…”

Section: Cytokinesmentioning

confidence: 99%

Inflammatory bowel disease and intestinal cancer: a paradigm of the Yin–Yang interplay between inflammation and cancer

Danese¹,

2010

View full text Add to dashboard Cite

Colon cancer represents a paradigm for the connection between inflammation and cancer in terms of epidemiology and mechanistic studies in preclinical models. Key components of cancer promoting inflammation include master transcription factors (for example, nuclear factor jB, STAT3), proinflammatory cytokines (for example, tumor necrosis factor, interleukin-6 (IL-6)), cyclooxygenase-2 and selected chemokines (for example, CCL2). Of no less importance are mediators that keep inflammation in check, including IL-10, transforming growth factorb, toll-like receptor and the IL-1 receptor inhibitor TIR8/ SIGIRR, and the chemokine decoy and scavenger receptor D6. Dissection of molecular pathways involved in colitis-associated cancer may offer opportunities for innovative therapeutic strategies.

show abstract

“…Sabe-se que o fator de necrose tumoral (TNF) alfa está elevado nas fezes, mucosa e sangue dos doentes com DC, e que o desequilíbrio entre secreção e sua inibição está relacionado com a patogênese da doença 13 . Neste contexto, algumas drogas foram desenvolvidas com a estratégia de bloqueá-lo e, demonstraram potente atividade clínica, confirmando o seu papel na patogênese da DC e no tratamento de doentes de difícil manejo clínico 5,15,17 .…”

Section: Introductionunclassified

Tratamento da doença de Crohn com infliximabe: primeira opção?

Malheiros¹,

Teixeira²,

Neto³

et al. 2009

ABCD, arq. bras. cir. dig.

View full text Add to dashboard Cite

INTRODUÇÃOO tratamento convencional da doença de Crohn (DC) é muitas vezes desapontador. Apesar da variedade de drogas disponíveis para o seu tratamento, tais como: salicilatos e seus derivados, corticosteróides, antibióticos e imunossupressores, nenhuma destas mostrou ser totalmente eficaz ou definitiva para o tratamento da doença e seus surtos de exacerbação. As drogas biológicas foram desenvolvidas com o objetivo de serem mais específicas para esse tipo de tratamento.Sabe-se que o fator de necrose tumoral (TNF) alfa está elevado nas fezes, mucosa e sangue dos doentes com DC, e que o desequilíbrio entre secreção e sua inibição está relacionado com a patogênese da doença 13 . Neste contexto, algumas drogas foram desenvolvidas com a estratégia de bloqueá-lo e, demonstraram potente atividade clínica, confirmando o seu papel na patogênese da DC e no tratamento de doentes de difícil manejo clínico 5,15,17 .Entre os variados tipos de anti-TNF alfa que surgiram para o tratamento da DC podemos citar: infliximabe, adalimumabe, CDP870, CDP571, etanercept e ornecept 17 . O infliximabe é um anticorpo monoclonal IgG1 quimérico constituído de 75% de proteína humana e 25% de proteína de camundongo. A porção de camundongo contém o sítio de ligação para o fator de necrose tumoral (TNF) alfa, enquanto a porção humana é responsável pela função efetora. O infliximabe liga-se ao TNF alfa solúvel e TNF ligado à membrana bloqueando as atividades biológicas da citocina 2,3 .O presente estudo visa avaliar os resultados obtidos com o uso do infliximabe no tratamento dos doentes com DC e observar se houve diferença na resposta clínica entre os grupos de doentes que variaram quanto ao tempo de doença e tratamento cirúrgico prévio relacionado. MÉTODO

show abstract

Secretion imbalance between tumour necrosis factor and its inhibitor in inflammatory bowel disease

Cited by 106 publications

References 49 publications

TNF‑α and soluble forms of TNF receptors 1 and 2 in the serum of patients with Crohn’s disease and ulcerative colitis

TNF‑α and soluble forms of TNF receptors 1 and 2 in the serum of patients with Crohn’s disease and ulcerative colitis

Inflammatory bowel disease and intestinal cancer: a paradigm of the Yin–Yang interplay between inflammation and cancer

Tratamento da doença de Crohn com infliximabe: primeira opção?

Contact Info

Product

Resources

About